share_log

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health, Inc. Announces Reverse Stock Split

捷豹健康公司宣佈反向股票拆分
Jaguar Health ·  05/17 12:00

Reverse split approved at April 2024 Special Meeting of Stockholders
Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024

2024 年 4 月股東特別會議批准了反向拆分
捷豹健康普通股將於2024年5月23日開始按拆分調整後的基礎上交易

SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-60, on Thursday, May 23, 2024 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX". The new CUSIP number for the Company's Common Stock following the reverse stock split is 47010C805.

加利福尼亞州舊金山/ACCESSWIRE/2024 年 5 月 17 日/ 捷豹健康公司 (納斯達克股票代碼:JAGX) (“捷豹” 或 “公司”)今天宣佈,公司將於2024年5月23日星期四(“生效日期”)以1比60的匯率對其已發行和流通的有表決權普通股(“普通股”)進行反向股票拆分,以支持公司遵守納斯達克的上市標準。該公司的普通股將在生效之日開盤時開始按拆分調整後的基礎上交易,並將繼續在納斯達克資本市場上市,股票代碼爲 “JAGX”。反向股票拆分後,公司普通股的新CUSIP號碼爲 47010C805。

"Jaguar's board of directors has determined that effecting a reverse stock split at this time will, in addition to supporting the Company's compliance with Nasdaq's listing standards, provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors," said Lisa Conte, Jaguar's president and CEO.

捷豹總裁兼首席執行官麗莎·孔戴錶示:“捷豹董事會已經確定,此時實施反向股票拆分除了支持公司遵守納斯達克的上市標準外,還將爲捷豹提供實現對機構投資者更具吸引力的股價和已發行股票數量的機會。”

The effectuation of the reverse stock split follows the approval of a proposal submitted to Jaguar stockholders at a Special Meeting of Stockholders (the "Special Meeting"). This proposal, which was approved by the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstention and broker non-votes) on such proposal by shares of Jaguar Common Stock and Series J Perpetual Preferred Stock of the Company outstanding as of the record date for the Special Meeting, is described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on March 15, 2024. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.

反向股票拆分是在股東特別會議(“特別會議”)上批准向捷豹股東提交的提案之後生效的。該公司向美國證券交易委員會提交的與特別會議有關的附表14A的最終委託書詳細描述了該提案,該提案在截至特別會議創紀錄日期的公司已發行的捷豹普通股和J系列永久優先股的該提案中獲得多數表決權持有者的贊成票(不包括棄權和經紀人不投票)。(“SEC”)於 2024 年 3 月 15 日。股東可以在以下地址免費獲得捷豹向美國證券交易委員會提交的委託書和其他文件的副本: http://www.sec.gov。委託書也可在公司的公司網站上查閱。

When the reverse stock split becomes effective, every sixty (60) shares of the Company's Common Stock immediately prior to the Effective Date shall automatically be reclassified into one (1) share of Common Stock, without any change in the par value per share, and this change will be reflected on Nasdaq's website and other stock quote platforms. No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof.

當反向股票拆分生效時,公司在生效日期之前的每六十(60)股普通股將自動重新分類爲一(1)股普通股,每股面值不發生任何變化,這一變化將反映在納斯達克的網站和其他股票報價平台上。由於反向股票拆分,不會發行任何零碎股票。原本有權獲得與反向股票拆分相關的部分股份的股東將獲得現金補助以代替。

Equiniti Trust Company, LLC is acting as exchange agent for the reverse stock split and will send instructions to stockholders of record who hold stock certificates regarding the exchange of their certificates for post-reverse stock split shares of Common Stock. Stockholders who hold their shares in brokerage accounts or "street name" are not required to take any action to effect the exchange of their shares.

Equiniti Trust Company, LLC是反向股票拆分的交易所代理,並將向持有股票證書的登記股東發出指示,要求他們交換反向股票拆分後的普通股證書。在經紀賬戶或 “街道名稱” 中持有股份的股東無需採取任何行動來進行股份交換。

About the Jaguar Health Family of Companies

關於 Jaguar Health 旗下公司

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing innovative, patient-centric therapeutic solutions for essential supportive care and the management of neglected side effects across complicated disease states. Napo's goal is to redefine what is possible in supportive care, providing hope and improving outcomes for patients worldwide. Napo's crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

Jaguar Health, Inc.(Jaguar)是一家商業階段的製藥公司,專注於開發可持續地從雨林地區植物中提取的新型專有處方藥,用於患有胃腸道不適的人和動物,特別與腸道過度活躍有關,包括慢性衰弱性腹瀉、尿急、腸失禁和抽筋痛等症狀。捷豹家族企業納波製藥(Napo)專注於開發創新的、以患者爲中心的治療解決方案,用於基本支持性護理和複雜疾病狀態中被忽視的副作用的管理。Napo的目標是重新定義支持性護理的可能性,爲全球患者提供希望並改善療效。Napo的crofelemer候選藥物產品是該研究的主題 OnTarg 該研究是一項關鍵的3期臨床試驗,用於對接受靶向治療的成年癌症患者化療誘發的腸道過度活躍(CIOB)進行預防性治療。捷豹家族企業Napo Therapeutics是一家意大利公司,捷豹於2021年在意大利米蘭成立,專注於擴大crofelemer在歐洲的使用範圍,特別是孤兒和/或罕見疾病。捷豹動物健康是捷豹的商品名。瑪格達萊納生物科學,由捷豹和Filament Health Corp. 組建的合資企業,從捷豹旗下崛起 Entheogen療法倡議 (ETI)專注於開發源自植物的新型處方藥,用於心理健康適應症。

For more information about:

有關以下內容的更多信息:

Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/

捷豹健康,訪問 https://jaguar.health
納波製藥,參觀 www.napopharma.com
Napo Therapeutics,請訪問 napotherapeutics.com
瑪格達萊納生物科學,訪問 magdalenabiosciences.com
在 LinkedIn 上訪問捷豹: https://www.linkedin.com/company/jaguar-health/
在 X 上訪問捷豹: https://twitter.com/Jaguar_Health
在 Instagram 上訪問捷豹: https://www.instagram.com/jaguarhealthcommunity/

Forward-Looking Statements

前瞻性陳述

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date, and the expectation that effecting a reverse stock split may provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

本新聞稿中的某些陳述構成 “前瞻性陳述”。其中包括關於捷豹預計該公司的普通股將在生效日市場開盤時開始按拆分調整後的基礎上進行交易的聲明,以及預計實施反向股票拆分可能使捷豹有機會實現對機構投資者更具吸引力的股價和已發行股票數量。在某些情況下,您可以使用 “可能”、“將”、“應該”、“預期”、“計劃”、“目標”、“預期”、“可能”、“打算”、“目標”、“項目”、“考慮”、“相信”、“估計”、“預測”、“潛在” 或 “繼續” 等術語來識別前瞻性陳述,或者這些術語或其他類似表述的否定詞。本新聞稿中的前瞻性陳述只是預測。捷豹的這些前瞻性陳述主要基於其當前對未來事件的預期和預測。這些前瞻性陳述僅代表截至本新聞稿發佈之日,受許多風險、不確定性和假設的影響,其中一些是無法預測或量化的,還有一些是捷豹無法控制的。除非適用法律要求,否則捷豹不計劃公開更新或修改此處包含的任何前瞻性陳述,無論是由於任何新信息、未來事件、情況變化還是其他原因。

Contact:

聯繫人:

SOURCE: Jaguar Health, Inc.

來源:捷豹健康公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論